TipRanks
Go Ultimate55% OFF

Rein Therapeutics (015A) Stock Forecast & Price Target

See the Price Targets and Ratings of:All AnalystsTop AnalystsPremium

015A Analyst Ratings

Moderate Buy
2Ratings
2Buy0Hold0Sell
Based on 2 analysts giving stock ratings to Rein Therapeutics in the past 3 months

015A Stock 12 Month Forecast

EUR 5.37▲(70.93% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Rein Therapeutics in the last 3 months. The average price target is EUR 5.37 with a high forecast of EUR 7.16 and a low forecast of EUR 3.58. The average price target represents a 70.93% change from the last price of EUR 3.14.
Highest Price TargetEUR 7.16Average Price TargetEUR 5.37Lowest Price TargetEUR 3.58

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:015A
Price TargetFollowArticle
Maxim GroupEUR 3.58buy13.95%UpsideReiterated10/22/26
H.C. WainwrightEUR 7.16buy127.91%UpsideReiterated09/21/26
Brookline Capital Markets―hold―Downgraded01/21/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OVIDOvid Therapeutics
REPLReplimune Group
IMUXImmunic
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rein Therapeutics

3 Months
Brandon Folkes
Brandon FolkesH.C. Wainwright
Success Rate2/8 ratings generated profit
25%
Average Return
-6.55%

Copying Brandon Folkes's trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -6.55% per trade.

1 Year
Brandon Folkes
Brandon FolkesH.C. Wainwright
Success Rate0/8 ratings generated profit
0%
Average Return
-34.55%

Copying Brandon Folkes's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -34.55% per trade.

2 Years
Brandon Folkes
Brandon FolkesH.C. Wainwright
Success Rate0/8 ratings generated profit
0%
Average Return
-39.92%

Copying Brandon Folkes's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -39.92% per trade.

015A Analyst Recommendation Trends

02468Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
Monthly rating counts for 015A
RatingJun 26Jul 26Aug 26Sep 26Oct 26
Strong Buy26662
Buy00000
Hold00000
Sell00000
Strong Sell00000
total26662

In the current month, 015A has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 015A average Analyst price target in the past 3 months is 5.37.

015A Financial Forecast

EUR -2EUR -1.5EUR -1EUR -0.5EUR 0Q3 2025Q2 2026Q3 2026
HighEUR -0.09
ConsensusEUR -0.09
LowEUR -0.09

015A Earnings Forecast

Next quarter’s earnings estimate for 015A is -EUR 0.09 with a range of -EUR 0.09 to -EUR 0.09. The previous quarter’s EPS was -EUR 0.09. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

EUR -1EUR -0.5EUR 0EUR 0.5EUR 1Q3 2025Q2 2026Q3 2026
HighEUR 0.00
ConsensusEUR 0.00
LowEUR 0.00

015A Sales Forecast

Next quarter’s sales forecast for 015A is EUR 0 with a range of EUR 0 to EUR 0. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

015A Stock Forecast FAQ

What is DE:015A’s average 12-month price target, according to analysts?
Based on analyst ratings, Rein Therapeutics’s 12-month average price target is €5.37.
What is DE:015A’s upside potential, based on the analysts’ average price target?
Rein Therapeutics has 70.93% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Rein Therapeutics a Buy, Sell or Hold?
Rein Therapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Rein Therapeutics’s share price target?
The average share price target for Rein Therapeutics is €5.37. This is based on 2 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €7.16, and the lowest forecast is €3.58. The average share price target represents a 70.93% increase from the current price of €3.143.
What do analysts say about Rein Therapeutics?
Rein Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Street analysts.
How can I buy shares of Rein Therapeutics?
To buy shares of DE:015A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.